{"entity":{"type":"insider","cik":"0001539739","url":"/insider/0001539739","json_url":"/insider/0001539739.json","name":"Occitan Capital Management Inc.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":50,"n_filings":2,"first":"2012-01-20","last":"2012-01-20","span_basis":"filed_date"},"name_variants":[{"name":"Occitan Capital Management Inc.","source":"filing","n_filings":2,"first_seen":"2012-01-20","last_seen":"2012-01-20"}],"transactions":[{"id":2939658,"accession":"0000945621-12-000011","txn_seq":20,"anchor":"line-20","filing_url":"/filing/0000945621-12-000011","line_url":"/filing/0000945621-12-000011","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":146700.0,"shares_display":"146,700","price_per_share":0.8024159509202454,"price_display":"0.80","price_state":"stated","total_value":117714.42,"total_display":"117,714.42","total_whole":"117,714","shares_owned_after":3763186.0,"shares_owned_after_display":"3,763,186","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-01-13","filed_date":"2012-01-20","scope":"insider","n_lines":9},{"id":2939627,"accession":"0000945621-12-000011","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000945621-12-000011","line_url":"/filing/0000945621-12-000011","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":28441.0,"shares_display":"28,441","price_per_share":0.860248760592103,"price_display":"0.86","price_state":"stated","total_value":24466.335,"total_display":"24,466.34","total_whole":"24,466","shares_owned_after":3666486.0,"shares_owned_after_display":"3,666,486","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-01-12","filed_date":"2012-01-20","scope":"insider","n_lines":6},{"id":2939605,"accession":"0000945621-12-000011","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000945621-12-000011","line_url":"/filing/0000945621-12-000011","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3900.0,"shares_display":"3,900","price_per_share":0.9199128205128205,"price_display":"0.92","price_state":"stated","total_value":3587.66,"total_display":"3,587.66","total_whole":"3,588","shares_owned_after":3648048.0,"shares_owned_after_display":"3,648,048","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-01-10","filed_date":"2012-01-20","scope":"insider","n_lines":5},{"id":2182464,"accession":"0000945621-12-000009","txn_seq":30,"anchor":"line-30","filing_url":"/filing/0000945621-12-000009","line_url":"/filing/0000945621-12-000009","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25675.0,"shares_display":"25,675","price_per_share":0.922458617332035,"price_display":"0.92","price_state":"stated","total_value":23684.125,"total_display":"23,684.12","total_whole":"23,684","shares_owned_after":3644045.0,"shares_owned_after_display":"3,644,045","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-01-10","filed_date":"2012-01-20","scope":"insider","n_lines":12},{"id":2182413,"accession":"0000945621-12-000009","txn_seq":18,"anchor":"line-18","filing_url":"/filing/0000945621-12-000009","line_url":"/filing/0000945621-12-000009","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20000.0,"shares_display":"20,000","price_per_share":0.940375,"price_display":"0.94","price_state":"stated","total_value":18807.5,"total_display":"18,807.50","total_whole":"18,808","shares_owned_after":3608470.0,"shares_owned_after_display":"3,608,470","ownership_form":"I","is_10b5_1":null,"transaction_date":"2012-01-06","filed_date":"2012-01-20","scope":"insider","n_lines":3},{"id":2182404,"accession":"0000945621-12-000009","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0000945621-12-000009","line_url":"/filing/0000945621-12-000009","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":18600.0,"shares_display":"18,600","price_per_share":0.847741935483871,"price_display":"0.85","price_state":"stated","total_value":15768.0,"total_display":"15,768.00","total_whole":"15,768","shares_owned_after":3577400.0,"shares_owned_after_display":"3,577,400","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-30","filed_date":"2012-01-20","scope":"insider","n_lines":3},{"id":2182396,"accession":"0000945621-12-000009","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000945621-12-000009","line_url":"/filing/0000945621-12-000009#line-12","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21070.0,"shares_display":"21,070","price_per_share":0.7949,"price_display":"0.79","price_state":"stated","total_value":16748.543,"total_display":"16,748.54","total_whole":"16,749","shares_owned_after":3598470.0,"shares_owned_after_display":"3,598,470","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-30","filed_date":"2012-01-20","scope":"insider"},{"id":2182393,"accession":"0000945621-12-000009","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000945621-12-000009","line_url":"/filing/0000945621-12-000009","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10500.0,"shares_display":"10,500","price_per_share":0.8125666666666667,"price_display":"0.81","price_state":"stated","total_value":8531.95,"total_display":"8,531.95","total_whole":"8,532","shares_owned_after":3596000.0,"shares_owned_after_display":"3,596,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-29","filed_date":"2012-01-20","scope":"insider","n_lines":2},{"id":2182386,"accession":"0000945621-12-000009","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0000945621-12-000009","line_url":"/filing/0000945621-12-000009","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":25500.0,"shares_display":"25,500","price_per_share":0.7929769215686274,"price_display":"0.79","price_state":"stated","total_value":20220.9115,"total_display":"20,220.91","total_whole":"20,221","shares_owned_after":3575000.0,"shares_owned_after_display":"3,575,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-28","filed_date":"2012-01-20","scope":"insider","n_lines":4},{"id":2182373,"accession":"0000945621-12-000009","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0000945621-12-000009","line_url":"/filing/0000945621-12-000009","is_derivative":false,"issuer_cik":"0001344413","issuer_name":"Alexza Pharmaceuticals Inc.","issuer_ticker":"ALXA","issuer_name_source":null,"issuer_url":"/issuer/0001344413","owner_cik":null,"owner_name":"OCCITAN MASTER FUND L.P.; Occitan Capital Management Inc.","owner_display_name":"OCCITAN MASTER FUND L.P.","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock, par value $0.0001","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11792.0,"shares_display":"11,792","price_per_share":0.8244835481682496,"price_display":"0.82","price_state":"stated","total_value":9722.31,"total_display":"9,722.31","total_whole":"9,722","shares_owned_after":3552600.0,"shares_owned_after_display":"3,552,600","ownership_form":"I","is_10b5_1":null,"transaction_date":"2011-12-23","filed_date":"2012-01-20","scope":"insider","n_lines":5}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001344413","name":"Alexza Pharmaceuticals Inc.","url":"/issuer/0001344413","role":"Ten percent owner, Other","n_filings":2,"first_seen":"2012-01-20","last_seen":"2012-01-20"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001539739","retrieved_at":"2026-08-26T09:36:38+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}